ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
To bolster its portfolio of chronic kidney disease treatments, AstraZeneca is paying roughly $2.7 billion to acquire ZS Pharma. With the deal, AstraZeneca gains ZS-9, a small molecule currently under FDA review as a treatment for hyperkalemia, or dangerously high potassium levels in the bloodstream of people with chronic kidney disease and chronic heart failure. FDA is expected to weigh in on ZS-9, a zirconium silicate that mimics natural ion channels to trap excess potassium ions, by May 2016. The firm believes ZS-9 could reach peak annual sales of more than $1 billion.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter